Results 51 to 60 of about 366,020 (324)
Primary goals, information-giving and men\u27s understanding: A qualitative study of Australian and UK doctors\u27 varied communication about PSA screening [PDF]
, 2017 Objectives: (1) To characterise variation in general practitioners’ (GPs’) accounts of communicating with men about prostate cancer screening using the prostate-specific antigen (PSA) test, (2) to characterise GPs’ reasons for communicating as they do ...
Carter, Stacy M +4 more
core +3 more sources
Molecular Oncology, EarlyView.Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece +18 more
wiley +1 more source
Urologic Clinics of North America, 1997 Prostate specific antigen is the "gold standard" prostate tissue marker. Based on a reviews of the literature, we present the metabolism, method and lassay clinical use for diagnosis, staging and prostate cancer as well as for monitoring response to treatment. The authors also discuss some situations able to increase the level of this marker.
Lori J. Sokoll, Daniel W. Chan
openaire +3 more sources
Qanun Medika: Jurnal Kedokteran Fakultas Kedokteran Universitas Muhammadiyah Surabaya, 2020 Benign prostatic hyperplasia (BPH) is one of the most common benign tumors in men with prevalence ranging from 50% for men in their 60s to 90% for men in their 80s.
Aulia Nur Fadila +2 more
doaj +1 more source
Prostate Specific Antigen (PSA) Inisial ? 100 Ng/ml Menggambarkan Stadium Lanjut Dan Rendahnya Survival Kanker Prostat [PDF]
, 2011 Prostate Specific Antigen(PSA) merupakanmarkeryang penting dalam diagnosis,follow up, dan menentukan prognosis kanker prostat. Penggunaan PSA sebagai skrining telah menurunkan kejadian kanker prostat stadium lanjut saat terdiagnosis.
Mochtar, C. A. (Chaidir) +2 more
core
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Moving ahead of prostate-specific antigen
Medical Journal of Dr. D.Y. Patil University, 2016 Prostate gland is the second most leading site of cancer among males in Indian cities and it is the second most common site of cancer among US men. Prostate cancer (PCa) is the sixth leading cause of cancer death among men worldwide.
Banyameen Mohamad Iqbal +1 more
doaj +1 more source
Molecular Oncology, EarlyView.The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués +3 more
wiley +1 more source
Recovery of zeta-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer. [PDF]
, 2002 Circulating T lymphocytes of patients with prostate cancer have been reported to have functional deficits, including low or absent zeta-chain expression.
Gooding, W +4 more
core
Prostate specific antigen in a community-based sample of men without prostate cancer: Correlations with prostate volume, age, body mass index, and symptoms of prostatism [PDF]
, 1995 The correlation between both prostate specific antigen levels (PSA) and prostate specific antigen density (PSAD) and age, prostate volume parameters, body mass index, and the International Prostate Symptom Score (IPSS) were studied in a community‐based ...
Bangma, C.H. (Chris) +4 more
core +2 more sources